Prolific Machines vs Regeneron
Side-by-side comparison of AI visibility scores, market position, and capabilities
Light-Activated Cell Growth & Biomanufacturing Technology
Prolific Machines is a Berkeley-based biotech company using light to control cell growth and differentiation, dramatically reducing bioreactor costs for cultivated meat and cell therapy; raised $55M+ including a $36M Series B in 2023;
About
Prolific Machines is a Berkeley, California-based biomanufacturing technology company founded in 2020 by Deniz Kent, Joshua Mich, and Declan Jones that has developed a pioneering approach to cell biology: using light — specifically engineered light-sensitive proteins (optogenetics) — to control the growth and differentiation of stem cells and other mammalian cells in bioreactors. Traditional cell culture requires expensive biological growth factors (proteins such as FGF2 and TGF-β) added to culture media to drive cell proliferation and differentiation. Prolific Machines'' technology replaces or dramatically reduces the need for these expensive growth factor inputs by using light signals to activate engineered receptors within cells — achieving the same biological responses at a fraction of the cost.
Tarrytown NY biopharma giant; creator of Dupixent (>$14B revenue), Eylea, and Kevzara. Velocity Genome platform drives fast antibody and bispecific drug discovery.
About
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized mouse technology that dramatically accelerates the discovery of human antibodies—and has used it to produce multiple best-in-class biologics across inflammatory, oncologic, and eye diseases.\n\nRegeneron's commercial portfolio is anchored by Dupixent (dupilumab), developed with Sanofi, which has become one of the best-selling drugs globally with over $14 billion in 2024 revenues, treating atopic dermatitis, asthma, COPD, and other type-2 inflammatory conditions. Additional key products include Eylea (aflibercept) for macular degeneration and PRALUENT for cardiovascular cholesterol lowering. The company's bispecific antibody pipeline, cancer vaccines in collaboration with BioNTech, and gene therapy programs represent its next growth wave.\n\nRegeneron reported over $14 billion in annual revenue in 2024 and maintains a world-class science culture, consistently ranking among the top companies for R&D productivity and employee satisfaction. Its Tarrytown campus houses more than 10,000 employees and remains a leading independent US biopharmaceutical innovator.
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.